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Strong	patent	rights	accelerate	the	diffusion	of	new
medicines	across	countries
In	1999	lovastatin,	a	blockbuster	cholesterol	drug	with	annual	peak	sales	of	more	than	$1	billion	in	the	U.S.,
became	commercially	available	in	Egypt	—	twelve	years	after	it	was	first	approved	for	sale	by	the	U.S.	Food	and
Drug	Administration.	Our	research	shows	that	this	is	not	exceptional	—	long	launch	lags	are	common	and	45	per
cent	of	all	new	drugs	are	only	launched	in	ten	or	fewer	countries	within	a	decade.	Since	delayed	launch	means
foregone	health	benefits,	it	is	important	to	understand	how	public	policy	affects	the	diffusion	of	new	drug
innovations.	Our	research	demonstrates	that	the	patent	and	price	regulation	policies	governments	adopt	have	a
powerful	impact	on	the	speed	at	which	new	drugs	become	available	in	different	countries,	and	this	is	true	both	for
countries	at	high	and	low	levels	of	economic	development.
Promoting	affordable	access	to	new	drugs	is	a	central	objective	of	government	policy.	This	poses	two	challenges:
providing	adequate	incentives	for	the	development	of	new	drugs,	and	ensuring	affordable	prices	of	drugs	once
developed.	Governments	use	two	main	instruments	to	achieve	these	goals:	patents	and	price	regulation.	
Economics	emphasizes	a	basic	trade-off	between	the	welfare	gains	from	stronger	innovation	incentives	provided
by	patents	and	the	welfare	loss	created	by	the	resulting	higher	prices.		Reflecting	this	concern,	most	research	on
patents	and	`access’	to	drugs	has	focused	on	how	the	1994	TRIPS	Agreement,	which	mandated	global
harmonization	of	pharmaceutical	patent	rights,	affected	prices	in	emerging	markets.
In	the	debates	over	TRIPS	and,	more	recently,	the	Trans-Pacific	Partnership	trade	agreement,	developing
countries	and	public	health	advocacy	groups	argued	that	harmonization	of	patent	policy	is	both	unnecessary	and
harmful	when	viewed	from	the	perspective	of	this	trade-off.	For	low-income	countries	with	limited	private	health
insurance	and	poorly	funded	public	health	systems,	the	welfare	loss	involves	not	just	the	deadweight	loss	from
higher	prices,	but	also	the	worrying	prospect	that	large	segments	of	the	population	may	have	no	affordable
access	to	new	drug	therapies.	This	has	led	economists	to	recommend	alternative	ways	for	governments	to
provide	innovation	incentives	while	maintaining	low	prices	in	developing	countries,	especially	for	vaccines.
Moreover,	the	increase	in	innovation	incentives	from	having	patent	rights	in	low-income	countries	is	likely	to	be
small	for	many	kinds	of	drugs	because	these	countries	do	not	account	for	a	large	part	of	the	global	market.
LSE Business Review: Strong patent rights accelerate the diffusion of new medicines across countries Page 1 of 4
	
	
Date originally posted: 2017-07-06
Permalink: http://blogs.lse.ac.uk/businessreview/2017/07/06/strong-patent-rights-accelerate-the-diffusion-of-new-medicines-across-countries/
Blog homepage: http://blogs.lse.ac.uk/businessreview/
This	debate,	however,	misses	a	critical	element:	the	impact	patent	rights	and	other	policies	have	on	the	diffusion
of	new	drugs.	The	public	health	benefits	of	new	drugs	depend,	first,	on	how	quickly	(if	at	all)	drugs	are	launched
in	different	countries	and,	second,	on	how	widely	they	are	adopted	within	a	country,	once	launched.	The	decision
to	launch	in	any	given	country	will	be	sensitive	to	drug	manufacturers’	assessment	of	anticipated	profits	relative	to
country-specific	costs.	These	include	costs	of	clinical	trials	to	secure	regulatory	approval	and	commercial	costs
relating	to	product	launch,	such	as	establishing	distribution	capacity,	educating	prescribers,	and	getting
reimbursement	from	private	or	public	insurers.	These	costs	must	be	incurred	in	every	country	in	which	a	drug	is
launched:	outside	tightly	integrated	trading	blocs	such	as	the	European	Union,	there	are	few	international
protocols	that	recognize	regulatory	approval	of	drugs	across	borders.	Moreover,	the	bulk	of	these	entry	costs
would	apply	whether	the	first	entrant	in	a	country	is	the	original	innovator,	its	licensee	or	a	generic	imitator.
If	the	sunk	investments	required	to	enter	and	penetrate	new	markets	are	significant,	the	diffusion	of	new
technologies	will	also	be	influenced	by	policies	that	affect	profitability	of	suppliers	in	different	markets,	including
patent	rights.	Of	course,	the	potential	role	of	patent	rights	in	promoting	global	diffusion	of	innovation	is	not	limited
to	pharmaceuticals,	but	they	are	a	good	case	study	both	because	of	their	economic	importance	and	the
significant,	country-specific	costs	of	launching	new	drugs.
In	this	research	we	study	how	patent	and	price	control	policies,	as	well	as	economic	and	demographic	factors,
affect	the	speed	and	scope	of	diffusion	of	new	pharmaceutical	products	across	countries.	The	empirical	analysis
is	based	on	a	large	data	set	that	covers	launches	of	642	new	drugs	(chemical	molecules)	in	up	to	76	countries
during	the	period	1983-2002,	together	with	information	on	the	patent	and	price	control	regimes	in	these	countries.
The	data	cover	countries	that	span	all	levels	of	economic	development	and	exhibit	a	wide	variety	of	patent
regimes.	In	the	analysis	we	distinguish	between	process	patents	and	product	patents	on	new	chemical
molecules.	Process	patents	are	considered	relatively	weak,	as	they	do	not	prevent	competitive	entry	by	entrants
with	superior	manufacturing	processes.	Some	countries	(such	as	India)	purposefully	adopted	a	`process	only’
patent	regime	for	drugs	in	order	to	foster	domestic	competitive	entry.	Product	patents	are	typically	considered
stronger	rights,	blocking	entry	by	competitive	(or	generic)	products	and	allowing	more	effective	appropriation	of
profit.
Our	research	demonstrates	four	main	findings.	First,	the	global	diffusion	of	new	drugs	is	slow.	Many	new	drugs
become	available	in	countries	only	after	long	lags	(often	more	than	10	years)	from	the	date	at	which	they	were
first	launched	commercially,	and	many	drugs	are	never	launched	outside	a	handful	of	wealthier	countries.
Second,	patent	policies	governments	adopt	strongly	affect	how	quickly	new	drug	therapies	are	launched	in	their
countries.	Longer,	and	stronger,	patent	protection	powerfully	accelerates	diffusion.	For	example,	controlling	for
economic	and	demographic	factors,	moving	from	a	regime	of	no	product	patents	to	a	long	product	patent	term
reduces	launch	lags	by	about	55	percent.	Process	patents	also	promote	faster	launch,	but	the	impact	is	not	as
large	as	for	product	patents.	Short	product	patents	have	no	effect.	Importantly,	we	show	that	the	impact	of	policy
regimes	holds	equally	for	low	and	middle-income	countries	as	for	high	income	countries.
Third,	countries	that	adopt	strong	pharmaceutical	price	controls	experience	significantly	longer	launch	lags	for
new	drugs.	We	estimate	that	introducing	price	controls	increases	launch	lags	by	between	25-80	per	cent.		Finally,
we	find	that	local	market	size	—	as	captured	by	population,	per	capita	income,	health	expenditures,	and
demographic	factors	—	has	a	big	impact	on	the	speed	of	drug	launches.
Of	course,	the	same	policies	that	promote	faster	launch	—	stronger	patent	rights	and	the	absence	of	price
regulation	—	are	also	those	that	raise	prices.	This	highlights	the	basic	trade-off	countries	face	between	making
new	drug	therapies	available	and	making	them	affordable.	Finding	ways	to	mitigate	the	adverse	effects	of	this
trade-off	remains	a	major	challenge.	One	possible	approach	would	be	to	introduce	multilateral	recognition	of	drug
trials	and	regulatory	approval,	lowering	launch	costs	and	speeding	up	global	drug	diffusion.	Finally,	our	paper
highlights	the	broader	point,	not	limited	to	pharmaceuticals,	that	patent	rights	can	have	an	important	impact	on
the	diffusion	of	new	innovations	as	well	as	on	the	rate	at	which	new	innovations	are	created.
Table	1.	Global	diffusion	of	new	drug	launches
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Table	1	presents	information	showing	how	many	countries	drugs	were	launched	in	(the	geographic	scope	of
diffusion).	The	striking	fact	is	that	diffusion	of	new	drugs	around	the	world	is	remarkably	limited.	For	the	entire
sample	of	new	drugs,	39	per	cent	were	launched	in	ten	or	fewer	countries	during	the	sample	period,	and	only	41
per	cent	were	launched	in	more	than	25	countries.	The	average	number	of	countries	experiencing	launch	is	22.4
out	of	a	possible	76.	Even	among	the	wealthier	countries	with	the	most	developed	health	care	systems,	not	all
drugs	became	available	during	the	sample	period:	e.g.,	only	about	60	per	cent	were	launched	in	the	U.S.,
Germany	or	the	U.K.	This	limited	geographic	diffusion	suggests	a	potentially	substantial	welfare	loss.	Even
among	the	set	of	‘high-quality’	drugs	(those	that	were	priority-reviewed	by	the	U.S.	Food	and	Drug	Administration,
FDA),	13	percent	of	new	drugs	were	launched	in	no	more	than	three	countries	within	the	sample	period.
The	problem	is	just	as	bad	when	we	turn	to	how	long	it	takes	drugs	to	be	launched.	For	all	drugs	and	countries
together,	we	find	that	after	10	years	only	41	per	cent	of	drug-country	opportunities	for	a	launch	were	taken	up	(not
shown	here).	Even	after	20	years	or	more,	less	than	50	per	cent	of	possible	launches	had	taken	place,	and	as
practical	matter,	many	of	these	drugs	may	never	be	launched	in	large	numbers	of	countries.	While	not	all	delays
necessarily	represent	welfare	losses	(some	drugs	may	have	become	obsolete,	may	have	no	value	in	contexts
where	important	complementary	technologies	or	resources	for	health	care	are	not	available,	or	may	only	be
useful	for	treating	diseases	with	low	incidence	in	a	country),	this	evidence	of	limited	diffusion	is	nonetheless
disappointing	from	a	welfare	perspective.	Even	in	the	sub-sample	of	FDA-approved	drugs,	only	54	per	cent	were
launched	in	the	average	country	within	10	years.	Diffusion	of	non-FDA-approved	drugs	was	much	slower	and	less
extensive,	with	19	per	cent	of	drug-country	launch	opportunities	filled	within	10	years.
Figure	1.	Fraction	of	drugs	launched	by	patent	regime
Figure	2.	Fraction	of	drugs	launched	by	price	controls
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Second,	the	speed	and	extent	of	diffusion	is	strongly	associated	with	a	country’s	patent	and	price	regulation
regimes.	Figure	1	shows	results	broken	out	by	a	summary	measure	of	each	country’s	patent	regime		–	None,
Short	(less	than	10	years),	Medium	(11-16	years)	and	Long	(17	years	or	longer).	With	no	patents,	the	estimated
time	for	25	percent	of	drug-country	launch	opportunities	to	be	filled	is	eight	years,	falling	to	less	than	2.6	years
with	long-duration	patents.	Figure	2	shows	that	in	countries	with	no	or	weak	price	regulation,	25	per	cent	of
launch	opportunities	are	filled	within	three	years,	compared	to	five	years	where	price	regulation	is	strong.
These	simple	comparisons	tell	the	story.		Of	course,	our	research	uses	modern	econometric	methods	to	confirm
these	basic	findings	when	we	control	for	a	wide	range	of	economic,	demographic	and	institutional	factors	that
may	also	influence	diffusion	speed.
This	research	broadens	the	intellectual	perspective	and	policy	discussion	on	patents	significantly,	because	the
focus	has	always	been	limited	to	the	how	patents	affect	the	incentives	for	innovation	on	the	one	side,	and	prices
on	the	other.	Our	research	shows	that	patent	rights	also	affect	the	availability	in	different	markets.	Importantly,
this	impact	would	be	expected	to	hold	for	any	products	where	there	are	significant	costs	of	launching	in	different
markets.	This	identifies	an	important	new	element	that	needs	to	be	taken	into	account	in	international	trade
agreements	that	cover	intellectual	property.
♣♣♣
This	blog	post	is	based	on	the	author’s	paper	Patents	and	the	Global	Diffusion	of	New	Drugs,	co-authored
with	Iain	M.	Cockburn	and	Jean	O.	Lanjouw,		American	Economic	Review	(2016)
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